AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,354 shares of the company’s stock after selling 616 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in AstraZeneca were worth $962,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Swedbank AB purchased a new stake in AstraZeneca during the first quarter worth about $186,127,000. Manning & Napier Advisors LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter valued at approximately $188,476,000. Hsbc Holdings PLC boosted its stake in shares of AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after acquiring an additional 1,132,362 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of AstraZeneca by 65.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after acquiring an additional 950,000 shares during the period. Finally, Fisher Asset Management LLC increased its stake in AstraZeneca by 5.3% in the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after purchasing an additional 524,175 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AZN shares. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. TD Cowen lifted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $66.40 on Tuesday. The stock has a market capitalization of $205.88 billion, a P/E ratio of 31.77, a P/E/G ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm’s 50-day moving average is $73.19 and its two-hundred day moving average is $77.72.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.87 earnings per share. Equities analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.